(12) **Translation of European patent specification**

(11) **NO/EP 2536706 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 401/04 (2006.01)
A61K 31/4412 (2006.01)
A61P 35/00 (2006.01)
C07D 401/14 (2006.01)
C07D 407/12 (2006.01)
C07D 407/14 (2006.01)
C07D 409/14 (2006.01)
C07D 413/14 (2006.01)
C07D 417/14 (2006.01)
C07D 487/04 (2006.01)
C07D 491/107 (2006.01)
C07D 493/04 (2006.01)
C07D 495/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.09.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.06.14
(86)	European Application Nr.	11704156.6
(86)	European Filing Date	2011.02.10
(87)	The European Application's Publication Date	2012.12.26
(30)	Priority	2010.02.11, US, 303618 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, US-USA
(72)	Inventor	MAN, Hon-Wah, 27 Grant Way, Princeton, NJ 08540, US-USA MULLER, George, W., P.O. Box 3688, Rancho Santa Fe, CA 92067, US-USA RUCHELMAN, Alexander, 15 Cutter Court, Cream Ridge, NJ 08514, US-USA KHALIL, Ehab, M., 305 Glebe Spring Lane, Yorktown, VA 23693, US-USA CHEN, Roger, Shen-Chu, 110 Christie St., Edison, NJ 08820, US-USA ZHANG, Weihong, 831-d Donaldson Street, Highland Park, NJ 08904, US-USA
(74)	Agent or Attorney	Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54) Title **ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME**

(56) References Cited:

WO-A2-2008/115516

NAKAMURA TAKANORI ET AL: "Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity.", December 2006 (2006-12), CHEMICAL & PHARMACEUTICAL BULLETIN DEC 2006 LNKD- PUBMED:17139107, VOL. 54, NR. 12, PAGE(S) 1709 - 1714, XP002628364, ISSN: 0009-2363 the whole document

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse med formel (I):



(I)

eller et farmasøytisk akseptabelt salt, solvat, eller stereoisomer derav, hvor:

X er C=O eller CH_2;

R^1 er -Y-R^3;

R^2 er H eller (C_1-C_6)alkyl;

Y er: 6 til 10 leddet aryl, heteroaryl eller heterocyklisk gruppe, som hver eventuelt kan være substituert med én eller flere halogen;

R^3 er:

-$(CH_2)_n$-aryl, -O-$(CH_2)_n$-aryl eller -$(CH_2)_n$-O-aryl, hvor arylet eventuelt er substituert med én eller flere: (C_1-C_6)alkyl, selv eventuelt substituert med én eller flere halogen; (C_1-C_6)alkoksy, selv substituert med én eller flere halogen; okso; amino; karboksyl; cyano; hydroksyl; halogen; deuterium; 6- til 10-leddet aryl eller heteroaryl, eventuelt substituert med én eller flere (C_1-C_6)alkyl, (C_1-C_6)alkoksy eller halogen; -$CONH_2$; eller -COO-(C_1-C_6)alkyl, hvor alkylet eventuelt kan være substituert med én eller flere halogen;

-$(CH_2)_n$-heterocyklisk gruppe, -O-$(CH_2)_n$-heterocyklisk gruppe eller -$(CH_2)_n$-O-heterocyklisk gruppe, hvor den heterocykliske gruppen eventuelt er substituert med én eller flere: (C_1-C_6)alkyl, selv eventuelt substituert med én eller flere halogen; (C_1-C_6)alkoksy, selv substituert med én eller flere halogen; okso; amino; karboksyl; cyano; hydroksyl; halogen; deuterium; 6- til 10-leddet aryl eller heteroaryl, eventuelt substituert med én eller flere (C_1-C_6)alkyl, (C_1-C_6)alkoksy eller halogen; -$CONH_2$; eller -COO-(C_1-C_6)alkyl, hvor alkylet eventuelt kan være substituert med én eller flere halogen; eller

-$(CH_2)_n$-heteroaryl, -O-$(CH_2)_n$-heteroaryl eller -$(CH_2)_n$-O-heteroaryl, hvor heteroarylet eventuelt er substituert med én eller flere: (C_1-C_6)alkyl, selv eventuelt substituert med én eller flere halogen; (C_1-C_6)alkoksy,

selv substituert med én eller flere halogen; okso; amino; karboksyl; cyano; hydroksyl; halogen; deuterium; 6- til 10-leddet aryl eller heteroaryl, eventuelt substituert med én eller flere (C_1-C_6)alkyl, (C_1-C_6)alkoksy eller halogen; -$CONH_2$; eller -COO-(C_1-C_6)alkyl, hvor alkylet eventuelt kan være substituert med én eller flere halogen; og

n er 0, 1, 2 eller 3;

hvor betegnelsen (C_1-C_6)alkyl omfatter (C_{3-6})cykloalkyl.

2. Forbindelse ifølge krav 1, hvor X er CH_2.

3. Forbindelse ifølge krav 1,

hvor Y er fenyl, og R^3 er -$(CH_2)_n$-heterocyklisk gruppe; eller

hvor Y er heteroaryl, og R^3 er -$(CH_2)_n$-heterocyklisk gruppe.

4. Forbindelse ifølge krav 1, som er:


































HCOO-
H2N








































































HCOOH






HCOO-

10











5







10







































5



eller et farmasøytisk akseptabelt salt, solvat eller stereoisomer derav.

5. Farmasøytisk preparat omfattende en forbindelse ifølge hvilke som helst av kravene 1-4, eller et farmasøytisk akseptabelt salt, solvat, eller stereoisomer derav.

6. Forbindelse ifølge hvilke som helst av kravene 1-5, eller et farmasøytisk akseptabelt salt, solvat, eller stereoisomer derav for anvendelse ved en fremgangsmåte for behandling, håndtering eller forhindring av en sykdom eller lidelse, hvor sykdommen eller lidelsen er kreft, en lidelse assosiert med angiogenese, smerte, makuladegenerasjon eller et relatert syndrom, en hudsykdom, en pulmonal lidelse, en asbestrelatert lidelse, a parasittisk sykdom, dysfunksjonell søvn eller en relatert lidelse, en infeksiøs sykdom, hemoglobinopati eller en relatert lidelse, eller en TNFα-relatert lidelse.